Journal of Renal Nutrition
Volume 11, Issue 1 , Pages 3-8 , January 2001

Vitamin D Analogs in Uremia: Integrating Medical and Nutritional Issues

  • Peggy Jernigan, MS, RD

      Affiliations

    • Renal Dietitian, Department of Veteran Affairs, Puget Sound Health Care System, Seattle, WA.
    • Corresponding Author InformationAddress reprint requests to Peggy Jernigan, RD, Department of Veteran Affairs, Puget Sound Health Care System, 1600 S Columbian Way, Dialysis Unit 111A, Seattle, WA 98108
    • ,
  • Dennis L. Andress, MD

      Affiliations

    • Staff Nephrologist, Department of Veteran Affairs, Puget Sound Health Care System, Seattle, WA.

References 

  1. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998;78:1193–1231
  2. Andress DL, Sherrard DJ. The osteodystrophy of chronic renal failure, in Schrier RW. In:  Gottschalk CW editors. Diseases of the Kidney. Boston, MA: Little, Brown; 1997;p. 2597–2624
  3. Torres A, Lorenzo V, Hernández D, et al. Bone disease in predialysis, hemodialysis and CAPD patients: Evidence of a better bone response to PTH. Kidney Int. 1995;47:1434–1442
  4. Rix M, Andreassen H, Eskildsen P. et al: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56:1084–1093
  5. Martinez I, Saracho R, Montenegro J. et al: The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496–502
  6. Schmitt CP, Huber D, Mehls O. et al: Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol. 1998;9:1832–1844
  7. Bro S. Olgaard K: Effects of excess PTH on nonclassical target organs. AmJ Kidney Dis. 1997;30:606–620
  8. Bouillon R, Carmeliet G, Daci E, et al. Vitamin D metabolism and action. Osteoporos Int. 1999;8:S13–S19(suppl)
  9. Ishimura E, Nishizawa Y, Inaba M, et al. Serum levels of 1, 25-dihydroxyvitamin D, 24, 25-dihydroxyvitamin Dand 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999;55:1019–1027
  10. Kurz P, Monier-Faugere M-C, Bognar B. et al: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46:855–861
  11. Slatopolsky E, Dusso A. Brown AJ: The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. AmJ Med Sci. 1999;317:370–376
  12. Kates DM, Sherrard DJ. Andress DL: Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am J Kidney Dis. 1997;30:809–813
  13. Block GA, Hulbert-Shearon TE, Levin NW. et al: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  14. Goodman WG, Goldin J, Knizon BD. et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  15. Rostand SG. Drüeke TB: Parathyroid hormone, vitamin Dand cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383–392
  16. Rao DS, Shih M-S. Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993;328:171–175
  17. Ghazali A, Fardellone P, Pruna A, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitfiol?. Kidney Int. 1999;55:2169–2177
  18. Bruce DG, St John A, Nicklason F, et al. Secondary hyperparathyroidism in patients from Western Australia with hip fracture: Relationship to type of hip fracture, renal functionand vitamin D deficiency. J Am Geriatr Soc. 1999;47:354–359
  19. Pei Y, Hercz G, Greenwood C. et al: Risk factors for renal osteodystrophy: A multivariant analysis. J Bone Miner Res. 1995;10:149–156
  20. Atsumi K, Kushida K, Yamazaki K. et al: Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999;33:287–293
  21. Brown AJ, Dusso A. Slatopolsky E: Vitamin D. Am J Physiol. 1999;277:F157–F175
  22. Quarles LD, Yohay DA, Carroll BA. et al: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994;45:1710–1721
  23. Goodman WG, Ramirez JA, Belin TR. et al: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994;46:1160–1166
  24. Brown AJ. Vitamin D analogues. Am J Kidney Dis. 1998;32:S25–S39(suppl 2)
  25. Kurokawa K, Akizawa T, Suzuki M, et al. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study. Nephrol Dial Transplant. 1996;11:121–124(suppl 3)
  26. Morii H, Ogura Y, Koshikawa S. et al: Efficacy and safety of oral falecalcitriol in reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. J Bone Miner Metab. 1998;16:34–43
  27. Martin KJ, González EA, Gellens M. et al: 19-nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998;9:1427–1432
  28. Finch JL, Brown AJ. Slatopolsky E: Differential effects of 1,25-dihydroxy-vitamin D 3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol. 1999;10:980–985
  29. Tan AU, Levine BS, Mazess RB. et al: Effective suppression of parathyroid hormone by 1-a-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 1997;51:317–323
  30. Frazao JM, Chesney RW, Cobum JW, et al. Intermittent oral la-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant. 1998;13:68–72(suppl 3)
  31. Knutson JC, LeVan LW, Valliere CR, et al. Pharmacokinetics and systemic effect on calcium homeostasis of 1,24-dihydroxyvitamin D2 in rats. Comparison with 1,25-dihy-droxyvitamin D2, calcitrioland calcipotriol. Biochem Pharmacol. 1997;53:829–837
  32. Mawer EB, Jones G, Davies M. et al: Unique 24-hy-droxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. J Clin Endocrinol Metab. 1998;83:2156–2166
  33. Takahashi F, Finch JL, Denda M, et al. A new analog of 1,25-(OH)2D 3, 19-NOR-1,25-(OH)2D 2 suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. AmJ Kidney Dis. 1997;30:105–112
  34. Harum P. Vitamin, mineral and hormone interactions in renal bone disease. J Ren Nutr. 1993;3:30–35
  35. Norris KC. Secondary hyperparathyroidism: Defining a model of optimal management. Dial Transplant. 1999;28:630–640
  36. Sanchez CP, Goodman WG. Salusky IB: Prevention of renal osteodystrophy in predialysis patients. Am J Med Sci. 1999;317:398–404
  37. Coburn JW, Elangovan L. Prevention of metabolic bone disease in the pre-end-stage renal disease setting. J Am Soc Nephrol. 1998;9:S71–S77(suppl)
  38. Levine BS. Song M: Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996;7:488–496
  39. Mclntyre CW, Schroeder NJ, Burrin JM. et al: Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease. Kidney Int. 1999;55:500–511
  40. In:  Wilkens KG,  Schiro KB editor. Suggested Guidelines for Nutrition Care of Renal Patients (ed 2). Chicago, IL: American Diabetes Association; 1992;
  41. Schiller LR, Santa Ana CA, Sheikh MS. et al: Effect of the time of administration of calcium acetate on phosphorus binding. N EnglJ Med. 1989;320:1110–1113
  42. Slatopolsky EA, Bunke SK, Dillon MA. Renagelê, a nonabsorbed calcium- and aluminum-free phosphate binder lowers serums phosphorus and parathyroid hormone. Kidney Int. 1999;55:299–307
  43. Hsu CH, Patel SR. Young EW: New phosphate binding agents: Ferric compounds. J Am Soc Nephrol. 1999;10:1274–1280
  44. Dewberry K, Fox JS, Stewart J, et al. Lanthanum carbonate: A novel non-calcium containing phosphate binder. J Am Soc Nephrol. 1997;8:560A;(abstr)
  45. Hoar S, Morton AR, Meers C. et al: A multidisciplinary approach to the control of the calcium × phosphate product in dialysis patients. Dial Transplant. 1999;28:309–313
  46. Poole R, Bell N. Diab A: Clinical outcome of calcitriol therapy and patient education program on hyperparathyroidism. J Ren Nutr. 1999;9:95–98
  47. Karmeil JC. The rehab exercise "E": A natural role for renal dietitians. J Ren Nutr. 1999;9:214–219

 Sponsored by an unrestricted educational grant from Bone Care International

PII: S1051-2276(01)11684-5

Journal of Renal Nutrition
Volume 11, Issue 1 , Pages 3-8 , January 2001

Article Tools